Our next CE event is scheduled for Monday, November 7th, 2022

Sponsored by IDEXX Laboratories

Cardiology Speaker Sponsor: Boehringer Ingelheim Animal Health

Drink Ticket Sponsor: Covetrus

 

Schedule of Events:

5:30-6:00pm: Check-In

6:00-6:50pm:  Dinner Seminar

Door prizes!

7:00-9:00pm: Lectures

To register, please refer to Invitation and Registration Form once they are available.  For any questions, reach out to Kristine Suszczynski at kristines@pvesc.com .

 

Dinner Lecture Topic:

Topic:  TBA

Presenter: Rebekah Mack-Gertig, DVM, BS, Ph.D., DACVIM(SAIM)

CEU Credits Pending

 

 

Veterinarian Lectures: 

Lecture A: Approaches to Diagnosis and Treatment of Paraneoplastic Syndromes 

Presenter:  Brittanie Partridge, DVM, Ph.D., DACVIM (Oncology) 7:00 p.m.

CEU Credits Pending

Paraneoplastic syndromes are a group of disorders that occur in the body at sites distant from the primary tumor and capable of significantly impacting our patients’ overall quality of life. In many cases, clinical changes associated with paraneoplastic syndromes precede diagnosis of the underlying cancer(s). Thus, these clinical changes may serve as early indicators of cancer, as well as markers of remission and cancer relapse. In some cases, the systemic effects induced by paraneoplastic syndromes may be more life-limiting to the patient than the underlying tumor itself, therefore, appropriate management of these conditions is critical to improving our patients’ overall prognosis. This lecture will use a case-based approach to highlight diagnostic and therapeutic approaches to the most common and most clinically significant paraneoplastic syndromes affecting our veterinary patients.

Lecture B: Synovetin – A Long Lasting Approach to Arthritis Control in Dogs and Cats

Presenter: Marta Agrodnia, DVM, DACVS-SA 8:00 p.m.

CEU Credits Pending

Synovetin is a medical radiotherapeutic injected into the joints of cats and dogs to control arthritic pain.  The tin 117 radio-isotope destroys the macrophages and synoviocytes, thus eliminating the cells which produce the inflammatory mediators responsible for arthritic pain.  When injected, the material is locked into the joint and does not undergo systemic excretion.  The treatment is provided on an outpatient basis, and one injection is expected to have roughly one year of pain relief.  The treatment is best provided in early stages of arthritis when it has a 90% response rate, but still provides a 75% response rate in dogs with more advanced arthritis.

 

Veterinary Technician and Veterinary Assistant Lectures:

Lecture C: Anesthesiology: More details to be announced 7:00 p.m.

Presenter: Raphael Vezina-Audette, MS, DVM, CVA, DACVAA

 

 

Lecture D: Anesthesiology: More details to be announced 8:00 p.m.

Presenter: Raphael Vezina-Audette, MS, DVM, CVA, DACVAA 

 

Sponsored by IDEXX Laboratories and Boehringer Ingelheim Animal Health.